Trend Scanner | Reports

From cost to collaboration: Redefining the value chain

Outsourcing (both supply chain and traditional back office functions)1 has been a regular feature of business life for many years. Through their responses to this survey, CEOs have indicated a marked shift in their motivation for using external suppliers, from simply as a mechanism to lower cost to a means of achieving a more strategic, collaborative framework. In tandem, CEOs tell us of an increasing trend to expand the scope of activity that is covered by outsourcing arrangements, from the traditional component supplies and IT infrastructure to other activities that, in the past, were held sacrosanct, including human resource management (HRM) and R&D.

2007

10th Annual global CEO Survey

PWC

view report

Organs-on-chips

Outside of Hollywood special effects shops, you won’t find living human organs floating in biology labs. Set aside all the technical difficulties with sustaining an organ outside the body—full organs are too precious as transplants to use in experiments. But many important biological studies and practical drug tests can be done only by studying an organ as it operates. A new technology could fill this need by growing functional pieces of human organs in miniature, on microchips. In 2010, Donald Ingber from the Wyss Institute developed a lung-on-a-chip, the first of its kind. The private sector quickly jumped in, with companies such as Emulate, headed by Ingber and others from the Wyss Institute, forming partnerships with researchers in industry and government, including DARPA, the U.S. Defense Advanced Research Projects Agency. So far, various groups have reported success making miniature models of the lung, liver, kidney, heart, bone marrow, and cornea. Others will certainly follow. Each organ-on-a-chip is roughly the size of a USB memory stick. It is made from a flexible, translucent polymer. Microfluidic tubes, each less than a millimeter in diameter and lined with human cells taken from the organ of interest, run in complex patterns within the chip. When nutrients, blood, and test compounds such as experimental drugs are pumped through the tubes, the cells replicate some of the key functions of a living organ. The chambers inside the chip can be arranged to simulate the particular structure of an organ tissue, such as a tiny air sac in a lung. Air running through a channel, for example, can then very accurately simulate human breathing. Meanwhile, blood laced with bacteria can be pumped through other tubes, and scientists can then observe how the cells respond to the infection, all without any risk to a person. The technology allows scientists to see biological mechanisms and physiological behaviors never before seen. Organ microchips will also give a boost to companies developing new medicines. Their ability to emulate human organs allows for more realistic and accurate tests of drug candidates. Last year, for example, one group used a chip to mimic the way that endocrine cells secrete hormones into the blood stream and used this to perform crucial tests on a diabetes drug. Other groups are exploring the use of organs-on-chips in personalized medicine. In principle, these microchips could be constructed using stems cells derived from the patients themselves, and then tests could be run to identify individualized therapies that are more likely to succeed. There is reason to hope that miniature organs could greatly reduce the pharmaceutical industry’s reliance on animal testing of experimental compounds. Millions of animals are sacrificed each year to such tests, and the practice provokes heated controversy. Ethical considerations aside, it has proven to be immensely wasteful—animal trials rarely provide reliable insights into how humans will react to the same drug. Tests done on miniaturized human organs might do better. Military and biodefence researchers see the potential for organs-on-chips to save lives in a different way. The simulated lung, and other devices like it, could be the next big step in testing responses to biological, chemical or radiological weapons. It isn’t possible to do this today, for obvious ethical reasons.

2016

Top 10 Emerging Technologies of 2016

World Economic Forum (WEF)

view report

The next frontier in power and commerce: Outer space

Outer space has emerged as a new strategic arena. Competition among countries to project power through space is intensifying as technological advances and growing commercial interests make outer space more accessible. These advances hold the promise of resource exploitation and territorial claims for human settlements. There are early parallels between what is happening in space and what happened in the seas in the colonial era. While these parallels hint that developments in space might be disorderly, they also suggest how nations could work together in the next frontier—through global rules for the global commons.

2017

Foresigth

Singapore, The Centre for Strategic Futures

view report

Frontier Disputes

Out to 2040, the position of international boundaries and frontiers is likely to be a source of tension. These tensions will either be between two opposing states, or, by an existing ethnic or nationalist group whose historic territories are divided by an international border. Most frontier disputes are settled amicably through legal arrangements. For example, in 2008 Russia and China settled a century old dispute regarding their Amur River border. However, other frontier disputes are less liable to be settled amicably, especially where ethnic differences are aggravated by inequality and also historical antagonism, and where access and ownership of scarce resources are involved.

2010